Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.
Location: United States, Illinois, Chicago
Employees: 51-200
Total raised: $81M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 06.08.2021 | Valor Equi... | valorep.co... |
| 25.10.2023 | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.10.2023 | Series B | $81M | - |
Mentions in press and media 12
| Date | Title | Description |
| 20.09.2024 | Free Webinar | October 30: How to Work With Family Offices to Raise Capital, Make Connections and Grow Your Business Did you know family offices currently have approximately $10 trillion in assets? Jo... | "Family Offices currently have approximately $10 Trillion in assets." - Ron Diamond, Chairman & CEO of Diamond Wealth and Family Office World Media Join us on October 30th at 2 pm ET to learn how to engage with Family Offices ... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 05.10.2023 | Evozyne: Novel Protein Systems Company Closes $81 Million In Series B Funding | Evozyne recently announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. Fidelity Management & Research Company and OrbiMed le... |
| 29.09.2023 | Evozyne Announces $81M Series B | CHICAGO, IL, Evozyne announced $81 Million in Series B funding led by Fidelity Management & Research Company and OrbiMed. >> Click here for more funding data on Evozyne >> To export Evozyne funding data to PDF and Excel,... |
| 28.09.2023 | Evozyne raises $81 million to use AI for drug discovery | - |
| 28.09.2023 | Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development | - |
| 27.09.2023 | Evozyne Raises $81M in Series B Financing | Evozyne, a Chicago, IL-based Generative AI company focused on therapeutic discovery and drug development, closed an $81m Series B funding round. The round was led by Fidelity Management & Research Company and OrbiMed with participation ... |
| 13.01.2023 | Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development | Evozyne revealed a breakthrough AI model, developed in collaboration with NVIDIA, that the pharmaceutical industry can use to design therapeutic proteins. Presented by NVIDIA at the J.P. Morgan Healthcare Conference in San Francisco, the no... |
| 12.01.2023 | Nvidia boosts generative AI for biology with BioNeMo | Check out all the on-demand sessions from the Intelligent Security Summit here. In September 2022, Nvidia announced the launch of its BioNeMo Large Language Model (LLM) service to help researchers build new artificial intelligence (AI) mode... |
Show more